INTERIM RESULTS OF A PHASE 3b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING 24-MONTH SAFETY OF ELAGOLIX WITH ADD-BACK FOR HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS
- Resource Type
- Abstract
- Source
- In
Fertility and Sterility October 2022 118(4) Supplement:e50-e51 - Subject
- Language
- ISSN
- 0015-0282